Your browser doesn't support javascript.
loading
Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men.
Hutchinson, J; Neesgard, B; Kowalska, J; Grabmeier-Pfistershammer, K; Johnson, M; Kusejko, K; De Wit, S; Wit, F; Mussini, C; Castagna, A; Stecher, M; Pradier, C; Domingo, P; Carlander, C; Wasmuth, J; Chkhartishvili, N; Uzdaviniene, V; Haberl, A; d'Arminio Monforte, A; Garges, H; Gallant, J; Said, M; Schmied, B; van der Valk, M; Konopnicki, D; Jaschinski, N; Mocroft, A; Greenberg, L; Burns, F; Ryom, L; Petoumenos, K.
Afiliação
  • Hutchinson J; The Australian HIV Observational Database (AHOD), The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
  • Neesgard B; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Kowalska J; Medical University of Warsaw, Warsaw, Poland.
  • Grabmeier-Pfistershammer K; Austrian HIV Cohort Study (AHIVCOS), Department Of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Johnson M; Department of Infectious Diseases and Hospital Epidemiology, Royal Free London NHS Foundation Trust, London, UK.
  • Kusejko K; University Hospital Zurich; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • De Wit S; Saint-Pierre University Hospital, Infectious Diseases Department, Université Libre de Bruxelles, Brussels, Belgium.
  • Wit F; AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, the Netherlands.
  • Mussini C; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Castagna A; Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy.
  • Stecher M; Italian Cohort Naive Antiretrovirals (ICONA), Milan, Italy.
  • Pradier C; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy.
  • Domingo P; University Hospital Cologne, Cologne, Germany.
  • Carlander C; Nice HIV Cohort, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France.
  • Wasmuth J; Sant Pau and Santa Creu Hospital, Barcelona, Spain.
  • Chkhartishvili N; Swedish InfCareHIV, Karolinska University Hospital, Solna, Sweden.
  • Uzdaviniene V; University Hospital Bonn, Bonn, Germany.
  • Haberl A; Georgian National AIDS Health Information System (AIDS HIS), Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.
  • d'Arminio Monforte A; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Garges H; Medical Center, Infectious Diseases Unit, Goethe-University Hospital, Frankfurt, Germany.
  • Gallant J; Italian Cohort Naive Antiretrovirals (ICONA), Milan, Italy.
  • Said M; ViiV Healthcare, RTP, Research Triangle Park, North Carolina, USA.
  • Schmied B; Gilead Sciences, Foster City, California, USA.
  • van der Valk M; European AIDS Treatment Group (EATG), Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Konopnicki D; Austrian HIV Cohort Study (AHIVCOS), Department Of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Jaschinski N; AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, the Netherlands.
  • Mocroft A; Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Greenberg L; Saint-Pierre University Hospital, Infectious Diseases Department, Université Libre de Bruxelles, Brussels, Belgium.
  • Burns F; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Ryom L; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Petoumenos K; Institute for Global Health, University College London, London, UK.
HIV Med ; 2024 Jun 05.
Article em En | MEDLINE | ID: mdl-38840507
ABSTRACT

BACKGROUND:

Women with HIV are globally underrepresented in clinical research. Existing studies often focus on reproductive outcomes, seldom focus on older women, and are often underpowered to assess sex/gender differences. We describe CD4, HIV viral load (VL), clinical characteristics, comorbidity burden, and use of antiretroviral therapy (ART) among women with HIV in the RESPOND study and compare them with those of the men in RESPOND.

METHODS:

RESPOND is a prospective, multi-cohort collaboration including over 34 000 people with HIV from across Europe and Australia. Demographic and clinical characteristics, including CD4/VL, comorbidity burden, and ART are presented at baseline, defined as the latter of 1 January 2012 or enrolment into the local cohort, stratified by age and sex/gender. We further stratify men by reported mode of HIV acquisition, men who have sex with men (MSM) and non-MSM.

RESULTS:

Women account for 26.0% (n = 9019) of the cohort, with a median age of 42.2 years (interquartile range [IQR] 34.7-49.1). The majority (59.3%) of women were white, followed by 30.3% Black. Most women (75.8%) had acquired HIV heterosexually and 15.9% via injecting drug use. Nearly half (44.8%) were receiving a boosted protease inhibitor, 31.4% a non-nucleoside reverse transcriptase inhibitor, and 7.8% an integrase strand transfer inhibitor. The baseline year was 2012 for 73.2% of women and >2019 for 4.2%. Median CD4 was 523 (IQR 350-722) cells/µl, and 73.6% of women had a VL <200 copies/mL. Among the ART-naïve population, women were more likely than MSM but less likely than non-MSM (p < 0.001) to have CD4 <200 cells/µL and less likely than both MSM and non-MSM (p < 0.001) to have VL ≥100 000 copies/mL. Women were also more likely to be free of comorbidity than were both MSM and non-MSM (p < 0.0001).

CONCLUSION:

RESPOND women are diverse in age, ethnicity/race, CD4/VL, and comorbidity burden, with important differences relative to men. This work highlights the importance of stratification by sex/gender for future research that may help improve screening and management guidelines specifically for women with HIV.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article